Slingshot members are tracking this event:

The FDA has set a Biosimilar User Fee Act target action date of Sept 14 2017 for ABP 215

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
AMGN Community voting in process
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Abp 215, Bsufa, Bevacizumab